College of Pharmacy, Dankook University, Dandae-ro 119, Dongnam, Cheonan, Chungnam 31116, Korea.
Bio-Center, Gyeonggido Business and Science Accelerator, Gwanggyo-ro 147, Yeoungtong, Suwon, Gyeonggi 16229, Korea.
Molecules. 2021 Mar 15;26(6):1638. doi: 10.3390/molecules26061638.
Crevost et Lemaire (Zingiberaceae) is a medicinal herb found in Southeast Asia that is used for the treatment of malaria, abdominal pain, dyspepsia, etc. The aim of this study was to investigate the effect of an ethanol extract of (EAT) on obesity and hyperlipidemia in C57BL/6 mice fed a high-carbohydrate diet (HCD). First, the mice were divided into five groups ( = 6/group) as follows: normal diet, HCD, and HCD+EAT (100, 200, and 400 mg/kg/day), which were orally administered with EAT daily for 84 days. Using microcomputed tomography (micro-CT) analysis, we found that EAT inhibited not only body-weight gain, but also visceral fat and subcutaneous fat accumulation. Histological analysis confirmed that EAT decreased the size of fat tissues. EAT consistently improved various indices, including plasma levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein, high-density lipoprotein, atherogenic index, and cardiac risk factors, which are related to dyslipidemia-a major risk factor for heart disease. The contents of TC and TG, as well as the lipid droplets of HCD-induced hepatic accumulation in the liver tissue, were suppressed by EAT. Taken together, these findings suggest the possibility of developing EAT as a therapeutic agent for improving HCD-induced obesity and hyperlipidemia.
Crevost et Lemaire（姜科）是一种在东南亚发现的药用草本植物，用于治疗疟疾、腹痛、消化不良等。本研究旨在探讨（EAT）对高碳水化合物饮食（HCD）喂养的 C57BL/6 小鼠肥胖和高血脂的影响。首先，将小鼠分为五组（每组 6 只）：正常饮食组、HCD 组和 HCD+EAT（100、200 和 400 mg/kg/天）组，每天口服给予 EAT 84 天。使用微计算机断层扫描（micro-CT）分析，我们发现 EAT 不仅抑制了体重增加，还抑制了内脏脂肪和皮下脂肪的积累。组织学分析证实 EAT 减小了脂肪组织的大小。EAT 一致改善了各种指标，包括血浆总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白、高密度脂蛋白、致动脉粥样硬化指数和心脏危险因素，这些与高血脂有关，高血脂是心脏病的主要危险因素。EAT 抑制了 HCD 诱导的肝组织中 TC 和 TG 的含量以及肝内脂质滴的积累。综上所述，这些发现表明 EAT 有可能作为改善 HCD 诱导的肥胖和高血脂的治疗剂。
